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INTRODUCTION                                                    
Tissue engineering (TE) is one of the ma-
jor components of regenerative medicine. 
Scientists in that field follow the principles of 
cell transplantation, materials science and en-
gineering to develop biologic substitutes that 
can restore and maintain normal function in 
a diseased organ1. Although the goals of TE 
are ambitious and have not yet been attained, 
significant milestones have been achieved 
and future possibilities are substantial. En-
gineered organs could sidestep many of the 
problems associated with donor organs, and 
at lower cost. Other equally promising ap-
plications, include conditions associated with 
tissue loss, such as strictures of the ureter and 
urethra, hypospadias, exstrophy-epispadias 
complex, bladder dysfunction in patients with 
myelomeningocele or traumatic spinal cord 
injury, and cystectomy for invasive bladder 
cancer2.
MATERIAL AND METHODS                                  
This review is based on a search of the 
PubMed database and recently published 
presentations at international Urology meet-
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ings. The literature analysis was performed 
between November 2008 and May 2009, and 
was accompanied by comparative discus-
sions of the current primary trends in TE ba-
sic research, experimental animal studies and 
clinical trials in vesical reconstruction.
RESULTS                                                            
Despite a marked increase in the number 
of articles about TE and stem cell research in 
the past few years, few papers describe blad-
der reconstruction utilizing TE approaches. 
The purpose of this article is to review recent 
developments in augmentation or substitution 
of the bladder. The described techniques have 
been successfully employed in experimental 
animal studies or in vitro systems, but only 
one study by Atala and colleagues (2006) has 
described augmentation cystoplasty in human 
subjects utilizing TE approaches.
Several varieties of TE techniques are cur-
rently under investigation, yet so far no single 
approach has been clearly superior based on 
significant long-term studies. The main goals 
of all techniques were to determine the opti-
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bladder cells from human patients, expand 
them in culture and return them to the donor 
in sufficient quantities for reconstructive 
purposes6. 
The success of cell cultures depends on 
utilizing recent techniques, such as fluores-
cence-activated cell sorting, immunomagne-
tic bead sorting, and magnetic-activated cell 
sorting. These recent techniques enabled the 
selection of specific cell types, and the targe-
ting of stem cell differentiation to the requi-
red cell type7.  
2- The role of biomaterials  
Biomaterials are essential for acellular 
or cell-based TE techniques. Biomaterials 
replicate the biologic and mechanical 
function of the native ECM proteins; in 
addition, they provide a three-dimensional 
space to form new tissues. Moreover, they 
can allow delivery of growing cells to the 
desired sites, and loading of bioactive factors 
that regulate cell function and behaviour.The 
ideal biomaterial should be biodegradable 
within a certain time, bioresorbable to 
support replacement of normal tissue without 
inflammation, and biocompatible to avoid 
foreign-body response8. 
Generally, three classes of biomaterials 
are used: (1) naturally derived materials 
that include collagen, the most abundant 
structural protein in the body,9 and alginate, 
a polysaccharide isolated from sea weed;10 
(2) acellular tissue matrices (decellularized 
bladder submucosa or small intestinal sub-
mucosa) which are collagen-rich matrices 
prepared by removing cellular components 
from small intestine mucosa or bladder 
mucosa;11 (3) synthetic polymers such as po-
lyglycolic acid (PGA), polylactic acid (PLA), 
and polylactic-co-glycolic acid (PLGA), 
which are polyesters of naturally occurring 
á-hydroxy acids11. 
3- The role of stem cells in TE  
Most current strategies for TE depend 
upon a sample of autologous cells from the 
diseased organ of the host. However, in cases 
mum scaffold that can be seeded by cells, and 
the best source of stem cells.
I- BASIC PRINCIPLES OF TISSUE 
ENGINEERING
TE strategies generally fall into two 
categories: the use of acellular matrices 
(tissue regeneration) or the use of cellular 
matrices.
A- The use of acellular matrices depends 
on the body’s natural ability to generate new 
tissue growth. Acellular tissue matrices are 
usually prepared from biomaterials to form 
artificial scaffolds. These matrices tend to 
slowly degrade on implantation and are gene-
rally replaced by extracellular matrix (ECM) 
proteins secreted by ingrowing cells3.
B- The use of matrices with cells depends 
(the subject of this sentence is “use”, not 
“cells”) upon an autologous sample of uro-
thelial and smooth muscle cells from the host 
tissue, obtained by small biopsies. These cells 
are either implanted directly into the host, or 
reimplanted into the host after expansion in a 
cell culture4. 
Autologous cells are the preferred type, 
as it does not induce host immune response, 
but there is a theoretical problem in using 
autologous cells from diseased organs. In-
vestigators reported a significant difference 
in the functional characteristics of cells ob-
tained from normal and diseased organs, and 
the clinical impact of this difference should 
be explored5. 
1- The role of cell culture and cell 
expansion  
Recent development of cell culture 
techniques allows (the subject of the sentence 
is “development”, not “techniques”) the 
expansion of a urothelial strain from a single 
specimen that initially covered a surface area 
of 1cm2, to one covering a surface area of 
4202 m2 within 8 weeks (the equivalent of 
one football field). These studies indicated 
that it should be possible to collect autologous 
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of end-stage organ failure, a tissue biopsy may 
not yield enough normal cells, or autologous 
cells cannot be expanded. In these situations 
alternative sources of cells can be derived 
from pluripotent stem cells by therapeutic 
cloning.12 Stem cells can be derived from 
discarded human embryos (human embryonic 
stem cells), from fetal tissue, from adult tissue 
(skin, fat, muscle, bone marrow, testes) 
and from amniotic fluid13.
There are two types of nuclear cloning: 
reproductive cloning and therapeutic cloning. 
Reproductive cloning is used to generate an 
embryo that has identical genetic material 
as its cell source. This embryo can then be 
implanted into the uterus of a female to give 
rise to an infant that is a clone of the donor 
individual. In 1997 a sheep named Dolly 
was the first mammal to be produced from 
adult somatic cells utilizing nuclear transfer 
techniques. In therapeutic cloning a donor 
nucleus is transferred into an enucleated oocyte 
to produce an early stage embryo, which is 
explanted into a tissue culture to provide a 
limitless source of human embroyonic stem 
cells whose genetic material is identical to 
that of its source. These autologous stem 
cells have the potential to proliferate into an 
undifferentiated but pluripotent state (self-
renewal) and has the ability to differentiate 
into many specialized cells of any type in 
the adult body. Therefore, it is considered 
the basis for cell transplantation and organ 
replacement applications, without inducing 
a host immune response or the need for a 
donated organ; it is likely to replace the use 
of autologous  organ-specific cells in the 
future14. 
The production of stem cells by 
therapeutic cloning has many limitations. It 
includes ethical issues, low efficiency of the 
cloning process and consumption of a large 
number of oocytes. Other problems include 
the scarcity of donated oocytes, possible 
congenital abnormalities, and the need to 
create scores of embryos to establish a single 
line of stem cells15. There are several trials 
to improve cloning efficiency by proper 
epigenetic reprogramming of the somatic 




 The stimulus for TE research in vesical 
reconstruction arises from the failure to re-
construct a bladder lined by urothelium. The 
benefits of enterocystoplasty carry a price, 
in the form of significant, well-documented 
complications that include mucus produc-
tion, stone formation, bacteriuria, metabolic 
disturbances, intestinal obstruction, and even 
malignancy17. 
Several alternatives have been explored 
to reconstruct a bladder lined by urothelium. 
These include the use of native urothelium 
derived either from a grossly dilated ureter 
(ureterocystoplasty) or from the bladder wall 
itself after excising the overlying detrusor 
muscle (auto-augmentation). Ureterocysto-
plasty is an attractive and clinically proven 
concept, but one which is effectively confi-
ned to a small minority of patients with gross 
ureteric dilatation. The long-term functional 
outcome of bladder auto-augmentation  has 
been disappointing18. Recent advances in the 
field of nanotechnology and stem cell biology 
provide alternative treatment by TE and neu-
romodulation19. 
The strategy of TE to reconstruct a blad-
der lined by urothelium can be grouped into 
two broad approaches: (1) in vivo tissue re-
generation and (2) in vitro TE utilizing two 
techniques, the cell-seeded, and non-seeded 
technology.
Cell-seeded technology uses scaffolds that 
are seeded in vitro with primary cultured cells 
obtained from a bladder biopsy. This compo-
site graft is then implanted back in the host. 
The non-seeded technology uses cell-free 
biodegradable scaffolds to allow the natural 
process of regeneration to occur in vivo20. 
It is unclear which approach is preferable. 
An experimental animal study comparing 
seeded and non-seeded scaffolds to recons-
truct the bladder in a canine model of sub-
total cystectomy recommended that cells are 
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necessary to achieve improved bladder tissue 
function, especially when a large amount of 
bladder tissue is required21.  
Tissue engineering approaches 
1- In vivo tissue regeneration using acellu-
lar matrices  
Taking advantage of the ability of the 
bladder to undergo rapid regeneration and 
repair after acute injury, a biomaterial 
implanted at the time of surgery becomes 
cellularized and eventually is assimilated 
into the tissues of the host bladder. Of all 
the synthetic and natural materials used to 
date, decellularized xenogeneic or allogeneic 
matrices prepared from the submucosa of 
small intestine and bladder have shown 
greatest promise. Experimental animal studies 
in rodent, canine and porcine models reported 
good tissue morphology and functional 
regeneration, but only to replace 30% to 40% 
of the required amount of bladder tissue22.     
Experimental studies with longer followup 
reported graft contraction and fibrosis leading 
to diminished bladder capacity. Due to the 
obvious advantage as an “off-the-shelf” 
solution for reconstructive bladder surgery, 
the authors preferred matrices implanted 
with cells to achieve the required amount 
of engineered bladder tissue with good 
function23.
2- In vitro tissue engineering    
A- Composite enterocystoplasty 
The potential complications of conventio-
nal enterocystoplasty are largely due to the 
unsuitability of the intestinal epithelium ra-
ther than the smooth muscle component of 
the bowel wall. For this reason, cell-culture 
techniques are employed to generate ade-
quate amounts of autologous urothelium for 
use in combination with de-epithelialized 
bowel segments. The observation of areas 
with incomplete urothelium covering, and 
others with re-growth of inappropriate host 
epithelium, prevents (subject of the sentence 
is “observation”) composite enterocystoplas-
ty from being realized as a clinical approach 
for bladder reconstruction. Nevertheless, it is 
an attractive strategy, as it requires only one 
component of the neobladder to be enginee-
red24.
B- Tissue engineered autologus neoblad-
der in experimental animals  
Bioengineering has allowed creation of 
functional neo-bladder tissues in several 
animal models. Autologous cells obtained 
by biopsy from the host were used to avoid 
rejection.The cells are dissociated and 
expanded in vitro, attached to a biodegradable 
matrix and re-implanted into the same host. 
After implantation, histological evidence 
showed that the engineered bladders 
continued to develop until they appeared 
normal anatomically and functionally25. 
The local and systemic effects of 
autologous neobladders engineered in canine 
models have been studied for 6 months 
postoperatively. The capacity and compliance 
of the engineered neobladder increased over 
time to normal levels. In addition, histological 
and immunohistochemical analyses showed 
that the engineered neobladder had adequate 
structural architecture, similar to that of native 
bladder. All other parameters including blood 
chemistry, urodynamics, cystography and 
urine analysis were normal26.  Current research 
suggests that bladders constructed in vitro 
may derive benefit from regular mechanical 
stimulation by a bladder tissue bioreactor. 
Such stimulation appears to induce favorable 
cellular changes essential for urinary bladder 
physiology27. 
C-Tissue engineered autologus neobladder 
in humans 
Atala and colleages (2006), after 17 years 
of basic research, conducted a clinical trial 
in seven patients with myelomeningocele, 
aged 4-19 years, with high-pressure or poorly 
compliant bladders and failure of medical 
treatment. A bladder biopsy was obtained 
from each patient. Urothelial and muscle 
cells were grown in culture, and seeded on a 
biodegradable bladder-shaped scaffold made 
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of a composite of collagen and polyglycolic 
acid for 7 weeks. The autologous engineered 
bladder constructs were implanted either 
with or without an omental wrap. The 
mean follow-up extended for 46 months. 
Serial urodynamics, cystography, ultrasound, 
bladder biopsy and serum biochemistry 
were done. Post-operative cystography and 
urodynamic studies showed improvement, 
especially in patients whose engineered 
bladder was covered with an omental wrap. 
Bowel function returned promptly after 
surgery with no metabolic consequences noted. 
Urinary calculi did not form, furthermore 
mucus production was normal, and renal 
function was preserved. They concluded 
that engineered bladder tissues, created 
with autologous cells seeded on collagen-
polyglycolic acid scaffolds, and wrapped in 
omentum after implantation, could be used in 
patients who require cystoplasty28.
DISCUSSION                                                        
Dramatic advances in the fields of 
biochemistry, cell and molecular biology, 
genetics, biomedical engineering and materials 
science have given rise to the remarkable 
new cross-disciplinary field of TE. Several 
technologies come together in TE that creates 
many controversies and difficulties to master 
all technological aspects.    
TE holds the promise for a tremendous 
impact on reconstructive urology. However, 
research must be intensified for the full 
potential clinical benefits to be made widely 
available. Engineered organs could avoid 
many of the hazards and problems associated 
with donor organs, and at lower cost. One of 
the most promising technologies for making 
artificial organs derives from work by Atala 
in the Wake Forest Institute for Regenerative 
Medicine, Winston-Salem, USA28. Atala has 
pioneered the field both as practitioner and as 
theorist in creating a functioning neobladder 
using a patient’s own cells.The engineered 
bladder was tailored to the individual and 
organs cannot yet be made for “off-the-shelf” 
distribution. Recently  a phase 2 clinical trial 
of the Tengion Neo-Bladder Augment™ 
for children with neurogenic bladder due to 
spina bifida was filed and accepted by the 
Food and Drug Administration. A clinical 
trial in patients with bladder cancer requiring 
total cystectomy will be initiated in the first 
half of 2010. 
In addition to resolving all specific basic 
research aspects of TE, legal discussions must 
support the movement of TE from theory to 
clinical application. Also, several areas of 
potential concern should be highlighted, 
including the possibility of introducing 
pathogenic agents, neoplastic transformation 
or congenital malformations resulting from 
TE29.
In conclusions; Despite the fact that 
TE is a recently developed and largely 
experimental field, it promises to influence 
urological treatment in the near future. 
Autologous neobladder cystoplasty had 
been applied successfully in humans, and it 
seems reasonable to predict that some form 
of urothelial TE will enter the clinical domain 
within the next 5 to 10 years.
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